Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 9/20 | 0.69 |
| ▸ | PARP1 | P09874 | 7/20 | 0.69 |
| ▸ | F7 | P08709 | 1/20 | 0.64 |
| ▸ | F3 | P13726 | 1/20 | 0.64 |
| ▸ | PARP11 | Q9NR21 | 5/20 | 0.56 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.56 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.56 |
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
| ▸ | DRD4 | P21917 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | TDP2 | O95551 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29438680 | 1.00 | PARP10 (0.69) | PARP10PARP1F7F3PARP11 | |
| SCHEMBL10201434 | 0.89 | PARP1 (0.56) | PARP10PARP1F7F3PARP11 | |
| SCHEMBL1417646 | 0.85 | PARP10 (0.64) | PARP10PARP1F7F3PARP11 | |
| SCHEMBL123731 | 0.81 | PARP10 (1.00) | PARP10PARP1F7F3PARP11 | |
| SCHEMBL29676851 | 0.81 | PARP10 (1.00) | PARP10PARP1F7F3PARP11 | |
| SCHEMBL29584703 | 0.81 | NTRK2 (0.56) | PARP10PARP1F7F3PBRM1 | |
| SCHEMBL4499446 | 0.81 | NTRK2 (0.56) | PARP10PARP1F7F3PBRM1 | |
| SCHEMBL23952279 | 0.78 | PARP10 (1.00) | PARP10PARP1F7F3PARP11 | |
| SCHEMBL793665 | 0.78 | PARP10 (0.64) | PARP10PARP1F7F3PARP11 | |
| SCHEMBL2619126 | 0.78 | PARP10 (1.00) | PARP10PARP1F7F3PARP11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260076975-A1 | TPK AGONIST AND METHOD FOR USING SAME TO TREAT NEURODEGENERATIVE DISEASES | SHANGHAI RAISING PHARMACEUTICAL CO LTD (CN) | 2026-03-19 | — | — | US | disclosed |
| US-20250320184-A1 | SARM1 MODULATORS, PREPARATIONS, AND USES THEREOF | SIRONAX LTD (KY) | 2025-10-16 | — | — | US | disclosed |
| EP-4628098-A1 | TPK AGONIST AND METHOD FOR USING SAME TO TREAT NEURODEGENERATIVE DISEASES | Shanghai Raising Pharmaceutical Co., Ltd. (CN) | 2025-10-08 | — | — | EP | disclosed |
| WO-2025096856-A1 | COVALENT CEREBLON LIGANDS | C4 THERAPEUTICS, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| EP-4077306-B1 | COMPOUNDS AND PROBES FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION INC (US) | 2025-05-07 | — | — | EP | disclosed |
| WO-2024114781-A1 | TPK AGONIST AND METHOD FOR USING SAME TO TREAT NEURODEGENERATIVE DISEASES | 上海日馨医药科技股份有限公司 | 2024-06-06 | — | — | WO | disclosed |
| CN-118121699-A | TPK agonists and methods of using the same for treating neurodegenerative diseases | 上海日馨医药科技股份有限公司 | 2024-06-04 | — | — | CN | disclosed |
| US-11992535-B2 | Compounds and probes for imaging huntingtin protein | CHDI FOUNDATION, INC. (US) | 2024-05-28 | — | — | US | disclosed |
| US-20240025875-A1 | A COMPOUND AS A THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20240025875-A1 | A COMPOUND AS A THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20070149585-A1 | Compounds useful as serotonin inhibitors and 5-HT1A agonists and antagonists | WYETH (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070093515-A1 | Phosphodiesterase 10 inhibitors | AMGEN INC. | 2007-04-26 | — | — | US | disclosed |
| US-20070093515-A1 | Phosphodiesterase 10 inhibitors | AMGEN INC. | 2007-04-26 | — | — | US | disclosed |
| WO-2007022280-A1 | PHOSPHODIESTERASE 10 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2007-02-22 | — | — | WO | disclosed |
| WO-2006138549-A1 | TRICYCLIC COMPOUNDS USEFUL AS SEROTONIN INHIBITORS AND 5-HT1A AGONISTS AND ANTAGONISTS | WYETH (US) | 2006-12-28 | — | — | WO | disclosed |
| WO-2006112464-A1 | PIPERAZINE-SUBSTITUTED BENZOTHIOPHENES FOR TREATMENT OF MENTAL DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-10-26 | — | — | WO | disclosed |
| WO-2006028957-A1 | 4-SUBSTITUTED 4, 6-DIALKOXY-CINNOLINE DERIVATIVES AS PHOSPODIESTERASE 10 INHIBITORS FOR THE TREATMENT OF PSYCHIATRIC OR NEUROLOGICAL SYNDROMS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2006-03-16 | — | — | WO | disclosed |
| US-20040110748-A1 | Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses | BEAVERS LISA SELSAM (US) | 2004-06-10 | — | — | US | disclosed |
| EP-1379493-A2 | NON-IMIDAZOLE ARYL ALKYLAMINES COMPOUNDS AS HISTAMINE H3 RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | Eli Lilly and Company (US) | 2004-01-14 | — | — | EP | disclosed |
| WO-2002076925-A2 | NON-IMIDAZOLE ARYL ALKYLAMINES COMPOUNDS AS HISTAMINE H3 RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2002-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250320184-A1 | SARM1 MODULATORS, PREPARATIONS, AND USES THEREOF | SARM1, SMN1; SMN2, ADRM1 | PARP10 697/4885PARP1 943/4885F7 4722/4885 |
| US-20240025875-A1 | A COMPOUND AS A THYROID HORMONE BETA RECEPTOR AGONIST AND USE THEREOF | THRB, TSHR, THRA | PARP10 4291/4885PARP1 4762/4885F7 2154/4885 |
| US-20070093515-A1 | Phosphodiesterase 10 inhibitors | PDE7A, PDE12, PDE10A | PARP10 197/4885PARP1 1264/4885F7 3883/4885 |
| US-20070149585-A1 | Compounds useful as serotonin inhibitors and 5-HT1A agonists and antagonists | HTR1A, HTR7, HTR3A | PARP10 2908/4885PARP1 3440/4885F7 2162/4885 |
| US-20260076975-A1 | TPK AGONIST AND METHOD FOR USING SAME TO TREAT NEURODEGENERATIVE DISEASES | PDXK, NADK, HYPK | PARP10 955/4885PARP1 1016/4885F7 3061/4885 |
| US-11992535-B2 | Compounds and probes for imaging huntingtin protein | HTT, HYPK, HSPBP1 | PARP10 1809/4885PARP1 3266/4885F7 4533/4885 |
| US-20040110748-A1 | Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses | HRH3, HRH4, HRH2 | PARP10 1138/4885PARP1 1610/4885F7 3174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.